An observational study in Mild Cognitive Impairment and Mild Dementia, sponsored by Ludwig-Maximilians - University of Munich. Recruiting at 1 site in Germany. Open to participants aged 60 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-01.
Sponsored by Ludwig-Maximilians - University of Munich · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 102 studies in Cognitive Dysfunction with a site in Germany — 20 open to participants now, 27 under way, 5 of them phase 3. Cognitive Dysfunction · Germany.
Among the 102 studies in Cognitive Dysfunction with a site in Germany, this one is the 3rd largest by planned enrollment of the 27 observational ones that give a count, is one of 11 that started in 2025, is one of 27 observational ones, reaches primary completion later than 13 of the 26 other live ones, and was the 86th registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →20 of the 102 studies in Cognitive Dysfunction with a site in Germany are open now. Recruiting first, the newest first:
Max Planck Institute for Human Cognitive and Brain Sciences · Sites in Germany
Ages 35–60 · Women only · Healthy volunteers
Henrik Bo Wiberg Larsson · Sites in Germany, Denmark
Ages 50–80 · Healthy volunteers
University Hospital, Bonn · Sites in Germany
Ages 50–80 · Healthy volunteers
University Medicine Greifswald · Sites in Germany
Ages 55–75 · Healthy volunteers
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 70+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 60 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
102 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 18 · Phase 4 4
First in 2004; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,020 is above the median of 150 across 1,000 observational studies indexed under Cognitive Dysfunction.
Median enrollment 100 across the 75 interventional studies, 124 across the 27 observational. Of the 58 that completed or were terminated, 14 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 102 have an industry lead sponsor. The 10 most frequent:
Ludwig-Maximilians - University of Munich is the lead sponsor of 223 studies on the registry; 29 are open to participants now.
Ludwig-Maximilians - University of Munich has 5 studies filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
6 of the studies in Cognitive Dysfunction with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT06207942Region SkaneStepcare Extended Follow-up Substudy | 2027-01 |
| NCT07114458Universitätsklinikum Hamburg-EppendorfDelirium and Cognitive Impairment Development in Hospitalized Older Adults Under Isolation Conditions | 2027-04 |
| NCT06652828University of OldenburgPerturbation-Based Treadmill Training to Prevent Unrecovered Falls in Geriatric Patients | 2027-04-30 |
| NCT07504965Ludwig-Maximilians - University of MunichDementia-friendly Apothecaries as a Resource for Mental Heath in the Elderly | 2027-07-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 102 studies in Cognitive Dysfunction with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The DARE study (Dementia-Friendly Apothecaries as a Resource for Mental Health in the Elderly) is a multicenter, prospective cohort study aiming to identify individuals with cognitive impairments early in pharmacies and enhance their access to support services. Partner pharmacies are equipped with memory test stations, and pharmaceutical staff are trained to guide participants. The digital memory test evaluates cognitive, psychosocial, and health factors, displaying results in a traffic light graphic. Participants with concerning results are referred to specialists or support services.
The study's primary goals are to establish pharmacies as dementia screening hubs, improve care for affected individuals, promote interdisciplinary collaboration, and lay the groundwork for legal and billing frameworks. An optional subproject validates the screening through neurological evaluations.
The DARE study (Dementia-Friendly Apothecaries as a Resource for Mental Health in the Elderly) is a multicenter, prospective cohort initiative designed to identify individuals with early cognitive impairments through pharmacies, making healthcare and support more accessible. It targets people with initial cognitive symptoms or mild dementia and aims to promote early intervention and improve quality of life.
Key Features:
Objectives:
Optional Subproject: A subset of participants undergoes additional clinical validation at the Alzheimer Therapy and Research Center, including neurological exams, imaging, and biomarker analysis.
The study emphasizes privacy through double pseudonymization, secure data handling, and adherence to ethical standards. It seeks to demonstrate the socioeconomic value of pharmacy-based dementia screening and create a framework for broader implementation.
Study Population:
The study population consists of individuals aged 60 and older, recruited from urban and rural pharmacies. Participants include those with self-reported, relative-reported, or pharmacist-identified cognitive impairments ranging from initial symptoms to mild dementia. The cohort emphasizes diversity, capturing various demographic factors such as migration background, education level, marital status, and living situations, with a focus on underrepresented and underserved groups, including isolated individuals and those in rural areas.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
These criteria aim to ensure that the study includes participants at risk of early cognitive decline while excluding those for whom the interventions or assessments would not be feasible or relevant.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study cohort for the DARE project includes customers and patients from pharmacies located in both urban and rural areas. These participants represent a diverse population segment, including individuals who might not regularly access traditional healthcare services, particularly in rural regions where medical facilities are less accessible. Cohort Details: 1. Eligibility Criteria: * Age: 60 years and older. * Cognitive impairments noted by participants themselves, relatives, or pharmacy staff. * Sufficient understanding of the German language. 2. Inclusion Focus: * Individuals with early cognitive symptoms or mild dementia. * Those potentially underserved by conventional healthcare systems, such as isolated or single individuals.
Change in WHOQOL-BREF psychological domain score
Quality of life will be assessed using the World Health Organization Quality of Life Questionnaire, Brief Version (WHOQOL-BREF). The primary outcome is the change in the psychological domain score from baseline to 24-month follow-up. The psychological domain score will be calculated according to the WHOQOL-BREF scoring manual and transformed to a 0-100 scale, with higher scores indicating better quality of life. Unit of Measure points (0-100 scale) Time Frame Baseline and 24 months
Time frame: 2025 - 2027
Healthcare utilization: number of healthcare contacts
Outcome Measure Title: Number of healthcare contacts Description: Healthcare utilization will be assessed using a structured study-specific questionnaire administered via telephone at 12- and 24-month follow-up. The outcome will be the number of healthcare contacts within the preceding 12 months, including visits to general practitioners, medical specialists, hospital admissions, and use of support services (e.g., counseling services, memory clinics, or social support programs). Unit of Measure: Number of contacts (count) Time Frame: 12 months and 24 months
Time frame: 2025 - 2027
Proportion of participants with new diagnosis of cognitive or neurological disorder
Description: New diagnoses will be assessed via participant self-report during structured telephone interviews at follow-up. The outcome is defined as the proportion of participants reporting a newly established diagnosis of a cognitive or neurological disorder (e.g., mild cognitive impairment or dementia) since baseline. Where feasible, diagnoses will be verified through available clinical documentation. Unit of Measure: Percentage of participants (%) Time Frame: 12 months and 24 months
Time frame: 2025 - 2027
Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.
Of 506 non-industry observational studies under Cognitive Dysfunction, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 118. This study's planned 24 months is below that.
Counting every sponsor, half of 545 studies reached it within 48 months; a quarter within 21 and three quarters within 118.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ludwig-Maximilians - University of Munich →